Hagens Berman probes CVRx after 59% stock drop and CRO exit
Hagens Berman investigates CVRx for securities fraud after a 59% stock drop triggered by a DOJ inquiry, reduced revenue guidance, and the firing of its CRO. The probe questions if investors were misled about sales force health and Medicare Advantage reimbursement rates, which fell from 80% to 25% approval within 30 days.
*this image is generated using AI for illustrative purposes only.
Law firm Hagens Berman has launched an investigation into CVRx, Inc. (NASDAQ: CVRX) for potential violations of federal securities laws, adding to the legal scrutiny already initiated by Block & Leviton. The new probe follows a 59% collapse in the company’s stock price on August 7, 2026, and focuses on allegations that CVRx misled investors about the severity of its operational crises and regulatory liabilities.
The investigation centers on three critical developments disclosed or occurring in August 2026: a civil investigative demand from the U.S. Department of Justice, a significant cut to full-year revenue guidance, and the abrupt termination of Chief Revenue Officer Robert John on August 10, 2026. Hagens Berman partner Reed Kathrein stated the firm is examining whether there is a direct connection between the DOJ inquiry and the CRO’s departure, as well as whether the true state of the commercial sales force and Medicare Advantage reimbursement rates were obscured from shareholders.
Escalating Legal and Operational Pressures
CVRx’s sole commercial product, Barostim, is an FDA-approved implantable neuromodulation device for heart failure patients. Historically, the company assured investors that its growth strategy was anchored by a completed sales force transformation and high approval rates from Medicare Advantage payers, citing a "$10.5 billion market opportunity" with less than 1% penetration.
However, disclosures made after market close on August 6, 2026, revealed severe headwinds:
- DOJ Civil Investigative Demand: On May 14, 2026, CVRx received a CID from the U.S. Department of Justice. The investigation examines whether the company caused the submission of false claims to government health programs by improperly marketing Barostim, paying kickbacks to healthcare providers, or submitting false information.
- Medicare Advantage Approval Collapse: The company revealed that its primary Medicare Advantage payer, which historically approved 80% of prior authorizations within 30 days, increased initial denials. Consequently, 30-day approvals dropped to just 25%.
- Sales Force Deterioration: CVRx reported sequentially flat growth in sales territories, high turnover, and strained onboarding processes, leading to the decision to lower its financial outlook.
Financial Guidance and Market Reaction
The catalyst for the initial legal scrutiny by Block & Leviton was CVRx’s announcement on August 6, 2026, that it was lowering its full-year revenue guidance to $58–60 million from a previous range of $63–67 million. The company attributed this miss to internal operational strains, specifically noting that rapid sales-force hiring had overwhelmed onboarding and training processes. This resulted in elevated turnover and slower productivity ramps for new territory managers, with nearly half of its regions reporting negative year-to-date implant growth.
Beyond internal issues, CVRx cited prolonged reimbursement challenges with one of its largest Medicare Advantage payers. The divergence between the prior and revised guidance highlights the severity of the execution gap, representing a potential loss of up to $9 million in expected annual revenue at the lower end of the prior estimate.
| Metric | Prior Guidance | Revised Guidance | Variance |
|---|---|---|---|
| Full-Year Revenue | $63–67 million | $58–60 million | Down to $9 million |
What the Numbers Show
The sharp contraction in revenue guidance coincides with a dramatic deterioration in reimbursement efficiency. The drop in Medicare Advantage approval rates from 80% to 25% within 30 days suggests a structural breakdown in the company’s primary revenue channel, rather than a temporary delay. This operational failure directly correlates with the $9 million downward revision in annual revenue expectations, indicating that the sales force instability and payer pushback have materially impaired top-line performance.
Investor Eligibility and Next Steps
Investors who purchased CVRx, Inc. common stock and experienced losses may be eligible to participate in potential class action lawsuits led by either firm. Eligibility extends to those who have not yet sold their investments. Both Block & Leviton and Hagens Berman have invited individuals with non-public information to contact them regarding the SEC whistleblower program, where rewards can reach up to 30% of successful recoveries.
How might the dual investigations by Hagens Berman and Block & Leviton impact CVRx's ability to secure additional capital or refinance existing debt given the heightened legal uncertainty?
Will the DOJ's civil investigative demand into potential kickbacks and false claims lead to broader regulatory scrutiny of other neuromodulation device manufacturers in the heart failure space?
What strategic alternatives, such as asset sales or partnership deals for Barostim, might CVRx pursue if Medicare Advantage reimbursement rates do not recover in the next two quarters?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
